Katona, G.; Sipos, B.; Budai-Szűcs, M.; Balogh, G.T.; Veszelka, S.; Gróf, I.; Deli, M.A.; Volk, B.; Szabó-Révész, P.; Csóka, I.
Development of In Situ Gelling Meloxicam-Human Serum Albumin Nanoparticle Formulation for Nose-to-Brain Application. Pharmaceutics 2021, 13, 646.
https://doi.org/10.3390/pharmaceutics13050646
AMA Style
Katona G, Sipos B, Budai-Szűcs M, Balogh GT, Veszelka S, Gróf I, Deli MA, Volk B, Szabó-Révész P, Csóka I.
Development of In Situ Gelling Meloxicam-Human Serum Albumin Nanoparticle Formulation for Nose-to-Brain Application. Pharmaceutics. 2021; 13(5):646.
https://doi.org/10.3390/pharmaceutics13050646
Chicago/Turabian Style
Katona, Gábor, Bence Sipos, Mária Budai-Szűcs, György Tibor Balogh, Szilvia Veszelka, Ilona Gróf, Mária A. Deli, Balázs Volk, Piroska Szabó-Révész, and Ildikó Csóka.
2021. "Development of In Situ Gelling Meloxicam-Human Serum Albumin Nanoparticle Formulation for Nose-to-Brain Application" Pharmaceutics 13, no. 5: 646.
https://doi.org/10.3390/pharmaceutics13050646
APA Style
Katona, G., Sipos, B., Budai-Szűcs, M., Balogh, G. T., Veszelka, S., Gróf, I., Deli, M. A., Volk, B., Szabó-Révész, P., & Csóka, I.
(2021). Development of In Situ Gelling Meloxicam-Human Serum Albumin Nanoparticle Formulation for Nose-to-Brain Application. Pharmaceutics, 13(5), 646.
https://doi.org/10.3390/pharmaceutics13050646